Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Response Genetics Achieves Third GSK Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Response Genetics Achieves Third GSK Milestone

Receives $500K for U.S. patent for detection of BRAF mutations

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Response Genetics has achieved its third milestone in its collaboration with GlaxoSmithKline related to the issuance of a U.S. patent for detection of BRAF Mutations, triggering a payment of $500,000 to Response Genetics.
 
The companies entered a non-exclusive license agreement in March 2010, under which GSK gained a non-exclusive license to Response Genetics PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples, in support of the development of GSK’s Tafinlar (dabrafenib). Response Genetics earned its first and second milestone payments totaling $1 million for the submission and subsequent Premarket Approval. 
 
“We are extremely pleased to have achieved this milestone,” said Thomas A. Bologna, chairman and chief executive officer of Response Genetics. “The BRAF patent approval is yet another example of the long-standing and mutually-beneficial relationship between Response Genetics and GSK. All of us at Response Genetics take pride in the role we played in the success of this important cancer therapy.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics